Sathy V. Balu-Iyer PhD

Sathy Balu-Iyer

Sathy V. Balu-Iyer
PhD


Professional Summary:

Research interest is in the area of protein delivery and immunotherapy.

Current research projects:

1. Development of lipidic nano particle containing therapeutic proteins and is supported by NHLBI/NIH. The overall goal of the project is to improve therapeutic efficacy of protein based therapies for bleeding and lysosomal disorders using a multidisciplinary approach involving Biophysics/Bioengineering, immunology and pharmacokinetics/Pharmacodynamics.

2. Re-activating Memory T Cells in the Microenvironment of Human Tumors and development of in situ vaccination. This project is supported by NCI/NIH (Dr. Bankert, PI, Balu-Iyer Co-PI). Our aim is to to rationally develop therapeutic intervention by understanding the molecular mechanism of TCR arrest.

3. Develop novel strategies to treat food allergies and autoimmune conditions using the tolerogenic properties of biomolecules.

4. Formulation and delivery of Monoclonal antibody based products: Understand and develop strategies to improve efficacy of antibody based therapeutics particularly given via sc route of administration

Education and Training:

  • PhD, Indian Institute of Science (1993)
  • MS/BA, Madurai Kamaraj University, India (1987)
  • Postdoctoral Fellow, Pharmaceutical Sciences - drug delivery, SUNY - University at Buffalo

Employment:

  • Professor (2012-present)
  • Adjunct Faculty (2000-present)
  • Associate Director (2000-present)
  • Associate Professor (2006–2012)
  • Assistant Professor (2000–2006)
  • Assistant Professor (2000)
  • Research Assistant Professor (1997–2000)
  • Post Doctoral Associate (1993–1996)
  • Post Doctoral Associate (1993)

Awards and Honors:

  • Fellow American Association of Pharmaceutical Sciences (2015)
  • Visionary Innovator Award (2015)
  • Innovation in Biotechnology Award (2012)
  • Exceptional Scholar Teaching Innovation Award (2011)
  • Inventor of the Year award 2011 (2011)
  • Nominated for Inventor of the year 2010 (2010)
  • Outstanding Reviewer - 2009 (2009)
  • Member, Editorial Board (2006)
  • Teacher of the Year Award (2006)
  • Reviewer Abstracts for poster and podium presentations (2005)
  • Guest Editor (2005)
  • Reviewer North Carolina Biotechnology Center Institutional Development (2004)
  • Reviewer Cooperative Grants Program (2003)
  • Mail reviewer (2003)
  • Inventor of the Year Award (2002)
  • First Patent Award (2002)

Research Expertise:

  • Immunotherapy: Develop lipid mediated tolerance strategies to overcome unwanted immune responses (protein and antibody therapeutics, allergies, autoimmune conditions and gene therapy)
  • Protein delivery and immunotherapy: Adopts an interdisciplinary approach of biophysics/bioengineering, pharmacokinetic and pharmacodynamic and immunology.
  • Protein formulation: Physicochemical and analytical methods of assessing protein structure, function, and stability in developing improved dosage forms.

Grants and Sponsored Research:

  • June 2022–May 2027
    Lipid mediated oral tolerance
    NIH/NIAID
    Role: Co-Principal Investigator
    $2,327,530
  • February 2002–December 2019
    Development and pharmacology of novel lipidic rAHF and Biotherapeutics
    NHLBI
    Role: Principal Investigator
    $1,000,000
  • June 2016–June 2018
    Investigation of formulation variables on sc bioavailability of monoclonal antibody therapeutics
    Role: Principal Investigator
    $148,000
  • July 2005–June 2006
    Product Development Fund
    University at Buffalo
    Role: Co-Principal Investigator
    $33,000

Patents:

  • Composition for less immunogenic and long circulating Protein-Lipid complex (2011)
  • Method for treating coagulation disorders (2011)
  • Method of complexing a protein by the use of a dispersed system and protein Type: Regular (2010)
  • Composition and method of preparation of micro particulate IL-12 (2010)
  • RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Other Other Type: Divisional (2008)
  • Compositions of less immunogenic and long circulating protein-lipid complex Type: Regular (2007)
  • Method for treating blood coagulation disorders Type: Regular (2007)
  • COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Europe (2007)
  • COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Canada (2007)
  • Composition and method of preparation of liposomal microparticulate IL-12 f Type: Regular (2006)
  • RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Other Other Type: Europe (2006)
  • COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: PCT (2006)
  • RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Other Other Type: Canada (2006)
  • COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Continuation-in-Part (2005)
  • Method and composition of pegylated phosphoserine complex (2005)
  • RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Regular (2004)
  • RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Other Other Type: PCT (2004)
  • COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Regular (2004)
  • COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: PCT (2004)
  • COMPOSITION OF THE RECONSTITUTIONAL MEDIUM FOR PROTEIN AND PEPTIDE FORMULAT Docket Number: 5847 Type: Provisional (2003)
  • METHOD FOR PREPARING PROTEIN-LIPID COMPLEXES WITH LOW IMMUNOGENICITY Docket Number: 5785 Type: Provisional (2003)
  • Stabilization of Taxane formulations (2002)
  • METHOD AND APPARATUS FOR HEATING AND CONTROLLING THE TEMPERATURE OF ULTRA S Docket Number: 0330 Type: Regular (1986)
  • COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Japan
  • COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Australia
  • COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: New Zealand

Journal Articles:

See all (52 more)

Professional Memberships:

  • American Society for Biochemistry and Molecular Biology (2005)
  • American Society for Biochemistry and Molecular Biology; nominated to become a Regular member in the American Society for Biochemistry and Molecular Biology (ASBMB) (2005–present)
  • Biophysical Society; Member (2003–present)
  • International Society on Thrombosis and Haemostasis; Member (2002–present)
  • American Association of Pharmaceutical Scientists (2000)
  • American Association of College Pharmacy; Member (2000)
  • American Association of Pharmaceutical Scientists; Member (2000–present)
  • Biophysical Society; Member (1995–1998)

Presentations:

  • "sc delivery of biotherapeutics" Dicerna, Dicerna (2015)
  • "Tricks of Modified Release of biologics" AAPS Annual Meeting, AAPS (2015)
  • "Role of immunogenicity in biological drug development" Workshop on Pharmacodynamics and Systems Pharmacology, Dublin City University (2014)
  • "Protein drugs; Formulation approaches for stabilizing biologics" FIP World congress of Pharmacy and Pharmaceutical Sciences, Dublin, FIP (2013)
  • "Reverse Vaccination and subcutaneous route – A novel strategy to mitigate immunogenicity" Abbvie, Abbvie (2013)
  • "Immunogenicity and Pharmacokinetics of subcutaneous administered therapeutic proteins" AAPS Biotechnology, AAPS (2013)
  • "Immunogenicity and pharmacokinetics of subcutaneously administered therapeutic proteins" AAPS NBC, AAPS, National Biotechnology Conference (2013)
  • "Lipid mediated Induction of Immunological Tolerance" Immunogenicity Summit 2012, Cambridge Health Tech (2012)
  • "Development of next generation protein therapeutics" NIAC, School of Pharmacy and Pharmaceutical Sciences (2012)
  • "Reverse Vaccination Lipid renders protein tolerogenic" AAPS Biotechnology, AAPS (2012)
  • "Mitigation of immunogenicity of Factor VIII by lipid mediated tolerance" IIR Annual Meeting, IIR (2012)
  • "Immunogenicity of Therapeutic Proteins" IIR Annual Meeting, IIR (2011)
  • "The pharmacokinetics and lymphatic exposure of recombinant human vascular endothelial growth factor VEGF-C156S after iv and sc administration" Pharmacology Day, University at Buffalo (2010)
  • "Phosphatidylserine and immune regulation to protein therapeutics" 11th annual immunogenicity for biotherapeutics, IIR USA (2010)
  • "(1) Multifunctional formulation approaches to reduce immunogenicity of protein therapeutics" New Jersey Pharmaceutical Association of Science and Technology, New Jersey Pharmaceutical Association of Science and Technology (2010)
  • "(2) Rational mechanism based formulation development to overcome Immunogenicity" Cambridge Health Tech PEP talk, Cambridge Heath Institute (2010)
  • "Immunogenicity of FVIII, a rational mechanism based formulation development" Protein stability conference, University of Colorado (2009)
  • "Development of lipidic recombinant Factor VIII to improve safety and efficacy of replacement therapy" Wyeth Andover (2009)
  • "Development and pharmacokinetic evaluation of liposomal VEGF-C156S." Great Lakes Symposium (2008)
  • "Formulation and biophysical characterization of liposomes encapsulating VEGF-C156S for PK/PD studies." Sigma Xi Research Conference (2008)
  • "Formulation and biophysical characterization of liposomes encapsulating VEGF-C156S for PK/PD studies." UB-Pfizer Conference (2008)
See all (11 more)

Service Activities:

  • Grant Reviewer; STW - Netherlands; Other (2010)
  • Organizing committee, Symposium nano for Medicine; Organize a national symposium on nanomedicine; Member (2009)
  • Department of Pharmaceutical Sciences Admissions committee; Member (2007–2019)
  • Life Sciences IRDF; Reviewer (2007)
  • Center for Protein Therapeutics; Member (2007)
  • Integrated NanoMedicine Search committee - Biological Sciences; Member (2007)
  • Integrated NanoMedicine Search committee; Member (2006)
  • Life Sciences Panel IRDF; To review proposals submitted for IRDF; Reviewer (2004)
  • UB2020 Integrated nano structures -chemical engineering; One of the author of the UB2020 integrated nano structures; Member (2003)
  • Curriculum committee; Member (2002)
  • Pharmaceutical Instrumentation Facility; Oversee pharmaceutical sciences Instrumentation facility, participate as Co I in shared equipment grants, train users managing the facility and trained users that have contributed to over 100 publication in peer reviewed journals, participated in several; Other (2000)
  • Pharmaceutical Sciences Instrumentation Facility; To oversee pharmaceutical instrumentation facility, participate in shared equipment proposal writing, train new users Successfully managing this instrumentation facility over several years that have contributed to over 100 peer-reviewed journal article,; Other (2000)
  • SOPPS Safety committe; Member (2000)
  • Accreditation Facilities sub-committe; Member
  • Author, UB2020 Integrated nano systems, white paper; Other
  • Committee; Therapeutic Protein Immunogenicity Focus GroupAAPS; Other
  • Course Reviewer; American Association of Pharmaceutical Scientists; Other
  • Distinguished speaking faculty; Cambridge Health Tech; Other
  • Distinguished speaking faculty; Institute for International Research; Other
  • Editorial Board; Asian Chemical Letters - Editorial Board; Other
  • Editorial Advisory Board; International Journal of Clinical research and Drug Development - Editorial Advisory Board; Other
  • Editorial advisory Board; Journal of Pharmaceutical Sciences - Editorial advisory Board; Other
  • Editorial advisory Board; Recent Patents on Endocrine, Metabolic & Immune Drug Discovery - Editorial advisory Board; Other
  • Faculty advisory committee, Integrated nano systems strategic strength; Member
  • Faculty Search Committee; Member
  • Graduate Student Admissions committee; Member
  • Graduate Student Admissions sub-committee; Member
  • Grant Reviewer; Israel Science Foundation; Other
  • Incubator and start-up committe; Member
  • Instrumentation Facility; Other
  • Member; American Association of Pharmaceutical Scientists; Other
  • Member; American Society for Biochemistry and Molecular Biology; Other
  • Participant, iHUB; Innovation HUB (iHUB), Science and Technology Transfer and Economic Outreach, University at Buffalo. iHUB is a federal grant awarded to UB from Economic Development Administration (EDA) to foster innovation, job creation and private capital investment in; Other
  • Pharm D faculty advisor; Academic advising for Pharm D students (3-4 students per year and total of 12-16 students); Other
  • Reviewer; Trinity College Ireland; Other
  • Reviewer/Presenter; Biotechnolgy 101 AAPS; Other
  • Undergraduate affairs committee; Member

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

359 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 645-4836
svb@buffalo.edu